Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16645047 | 0.84 | LMNA (0.40) | LMNAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL15694283 | 0.84 | LMNA (0.40) | LMNAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL10063804 | 0.84 | LMNA (0.40) | LMNAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL6704843 | 0.82 | TDP1 (0.40) | LMNAL3MBTL1TDP1KDM4E | |
| SCHEMBL14241067 | 0.80 | TDP1 (0.38) | LMNAL3MBTL1TDP1KDM4E | |
| SCHEMBL10082714 | 0.80 | TDP1 (0.38) | LMNAL3MBTL1TDP1KDM4E | |
| SCHEMBL14391622 | 0.80 | TDP1 (0.38) | LMNAL3MBTL1TDP1KDM4E | |
| SCHEMBL13719184 | 0.80 | TDP1 (0.38) | LMNAL3MBTL1TDP1KDM4E | |
| SCHEMBL15731250 | 0.80 | TDP1 (0.38) | LMNAL3MBTL1TDP1KDM4E | |
| SCHEMBL15731076 | 0.80 | TDP1 (0.38) | LMNAL3MBTL1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8262867-B2 | Metal alkoxides, apparatus for manufacturing metal alkoxides, related methods and uses thereof | AUTERRA, INC. (US) | 2012-09-11 | — | — | US | claimed |
| JP-2011504880-A | — | — | 2011-02-17 | — | — | JP | claimed |
| EP-2217387-A1 | METAL ALKOXIDES, APPARATUS FOR MANUFACTURING METAL ALKOXIDES, RELATED METHODS AND USES THEREOF | Auterra, Inc. (US) | 2010-08-18 | — | — | EP | claimed |
| US-20100179339-A1 | METAL ALKOXIDES, APPARATUS FOR MANUFACTURING METAL ALKOXIDES, RELATED METHODS AND USES THEREOF | AUTERRA, INC. (US) | 2010-07-15 | — | — | US | claimed |
| WO-2009070420-A1 | METAL ALKOXIDES, APPARATUS FOR MANUFACTURING METAL ALKOXIDES, RELATED METHODS AND USES THEREOF | APPLIED NANOWORKS, INC. (US) | 2009-06-04 | — | — | WO | claimed |
| US-20090134369-A1 | METAL ALKOXIDES, APPARATUS FOR MANUFACTURING METAL ALKOXIDES, RELATED METHODS AND USES THEREOF | APPLIED NANOWORKS, INC. (US) | 2009-05-28 | — | — | US | claimed |
| US-10173189-B2 | Method for preparing a suspension containing carbon nanotubes and stable suspension obtained in this way | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2019-01-08 | — | — | US | disclosed |
| US-20160362300-A1 | METHOD FOR PREPARING A SUSPENSION CONTAINING CARBON NANOTUBES AND STABLE SUSPENSION OBTAINED IN THIS WAY | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2016-12-15 | — | — | US | disclosed |
| US-9028768-B2 | Metal alkoxides, apparatus for manufacturing metal alkoxides, related methods and uses thereof | AUTERRA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-8877131-B2 | Metal alkoxides, apparatus for manufacturing metal alkoxides, related methods and uses thereof | AUTERRA, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8262867-B2 | Metal alkoxides, apparatus for manufacturing metal alkoxides, related methods and uses thereof | AUTERRA, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2217387-A1 | METAL ALKOXIDES, APPARATUS FOR MANUFACTURING METAL ALKOXIDES, RELATED METHODS AND USES THEREOF | Auterra, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20100179339-A1 | METAL ALKOXIDES, APPARATUS FOR MANUFACTURING METAL ALKOXIDES, RELATED METHODS AND USES THEREOF | AUTERRA, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| WO-2009070420-A1 | METAL ALKOXIDES, APPARATUS FOR MANUFACTURING METAL ALKOXIDES, RELATED METHODS AND USES THEREOF | APPLIED NANOWORKS, INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20090134369-A1 | METAL ALKOXIDES, APPARATUS FOR MANUFACTURING METAL ALKOXIDES, RELATED METHODS AND USES THEREOF | APPLIED NANOWORKS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| EP-1310532-B1 | Phase change inks containing borate esters | XEROX CORP (US) | 2006-05-17 | — | — | EP | disclosed |
| US-6682591-B2 | HYDROLYTICALLY STABLE | XEROX CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-20030127020-A1 | Aqueous ink compositions containing borate esters | XEROX CORPORATION | 2003-07-10 | — | — | US | disclosed |
| US-6585816-B1 | As vehicle for thermal ink jet printing; nonevaporating, nonspilling | XEROX CORPORATION | 2003-07-01 | — | — | US | disclosed |
| EP-1310532-A1 | Phase change inks containing borate esters | Xerox Corporation (US) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179339-A1 | METAL ALKOXIDES, APPARATUS FOR MANUFACTURING METAL ALKOXIDES, RELATED METHODS AND USES THEREOF | ADH1A, AKR7A2, PAOX | LMNA 3710/4885L3MBTL1 2674/4885TDP1 3562/4885 |
| US-20090134369-A1 | METAL ALKOXIDES, APPARATUS FOR MANUFACTURING METAL ALKOXIDES, RELATED METHODS AND USES THEREOF | ADH1A, AKR7A2, PAOX | LMNA 3710/4885L3MBTL1 2674/4885TDP1 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.